X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse AJANTA PHARMA with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AJANTA PHARMA   MYLAN
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
MYLAN
Dec-14
AJANTA PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,7203,795-   
Low Rs1,1032,674-   
Sales per share (Unadj.) Rs194.61,299.1-  
Earnings per share (Unadj.) Rs45.2156.5-  
Cash flow per share (Unadj.) Rs50.3251.9-  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.0645.8-  
Shares outstanding (eoy) m88.77378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x7.32.5 291.3%   
Avg P/E ratio x31.220.7 151.0%  
P/CF ratio (eoy) x28.112.8 218.6%  
Price / Book Value ratio x10.75.0 213.4%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,2991,223,813 10.2%   
No. of employees `000NA25.0 0.0%   
Total wages/salary Rs m2,5700-   
Avg. sales/employee Rs ThNM19,661.3-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM2,368.5-  
INCOME DATA
Net Sales Rs m17,275491,532 3.5%  
Other income Rs m166-2,865 -5.8%   
Total revenues Rs m17,442488,667 3.6%   
Gross profit Rs m5,807122,246 4.8%  
Depreciation Rs m45136,101 1.2%   
Interest Rs m4921,202 0.2%   
Profit before tax Rs m5,47462,078 8.8%   
Minority Interest Rs m0-255 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4602,610 55.9%   
Profit after tax Rs m4,01459,213 6.8%  
Gross profit margin %33.624.9 135.2%  
Effective tax rate %26.74.2 634.2%   
Net profit margin %23.212.0 192.9%  
BALANCE SHEET DATA
Current assets Rs m7,639432,122 1.8%   
Current liabilities Rs m2,715337,833 0.8%   
Net working cap to sales %28.519.2 148.6%  
Current ratio x2.81.3 220.0%  
Inventory Days Days4378 55.4%  
Debtors Days Days79107 73.3%  
Net fixed assets Rs m6,914113,715 6.1%   
Share capital Rs m17717,382 1.0%   
"Free" reserves Rs m11,4420-   
Net worth Rs m11,721244,340 4.8%   
Long term debt Rs m149365,020 0.0%   
Total assets Rs m14,814984,179 1.5%  
Interest coverage x112.93.9 2,875.4%   
Debt to equity ratio x01.5 0.8%  
Sales to assets ratio x1.20.5 233.5%   
Return on assets %27.48.2 335.7%  
Return on equity %34.224.2 141.3%  
Return on capital %46.513.6 341.5%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Net fx Rs m8,7440-   
CASH FLOW
From Operations Rs m3,26464,612 5.1%  
From Investments Rs m-2,093-50,955 4.1%  
From Financial Activity Rs m-1,186-17,025 7.0%  
Net Cashflow Rs m-15-3,368 0.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 63.67 Rs / USD

Compare AJANTA PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare AJANTA PHARMA With: MERCK LTD  BIOCON LTD  VENUS REMEDIES  DISHMAN PHARMA  IPCA LABS  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 16, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS